International Stem Cell (ISCO) Cost of Revenue (2010 - 2026)
International Stem Cell (ISCO) posted quarterly Cost of Revenue of $1.1 million for Q4 2025, up 7.68% year-over-year from $990000.0 in Q4 2024, and up 1.72% quarter-over-quarter from $1.0 million in Q3 2025.
International Stem Cell (ISCO) Cost of Revenue (2010 - 2026) Analysis & Trends
International Stem Cell (ISCO) has reported Cost of Revenue for 16 consecutive years, with $1.1 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Cost of Revenue rose 7.68% year-over-year to $1.1 million; the TTM figure through Dec 2025 stood at $4.0 million (up 7.15% YoY), while the FY2025 annual figure was $4.0 million, up 7.15% from the prior year.
- Cost of Revenue climbed to $1.1 million in Q4 2025 per ISCO's latest filing, from $1.0 million in the prior quarter.
- Across five years, Cost of Revenue topped out at $1.1 million in Q4 2022 and bottomed at $615000.0 in Q1 2021.
- Historically, Cost of Revenue has averaged $859050.0 across 5 years, with a median of $843500.0 in 2023.
- Annual changes were most pronounced in 2021 — Cost of Revenue declined 28.24% — and 2022, when it soared 54.56%.
- International Stem Cell's Cost of Revenue stood at $735000.0 in 2021, then jumped by 54.56% to $1.1 million in 2022, then declined by 24.03% to $863000.0 in 2023, then rose by 14.72% to $990000.0 in 2024, then advanced by 7.68% to $1.1 million in 2025.
- Business Quant data shows ISCO's Cost of Revenue at $1.1 million in Q4 2025, $1.0 million in Q3 2025, and $927000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 489.20 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 360.70 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 145.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 93.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 174.53 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 298.26 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 67.21 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 387.98 Mn |
| 10 | International Stem Cell | 4.32 Mn | 3.23 Mn | 1.46 Mn | 1.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.22 Mn |
| Jun 30, 2026 | 1.22 Mn |
| Dec 31, 2025 | 1.07 Mn |
| Dec 31, 2025 | 1.07 Mn |
| Sep 30, 2025 | 1.05 Mn |
| Sep 30, 2025 | 1.05 Mn |
| Jun 30, 2025 | 927,000.00 |
| Jun 30, 2025 | 927,000.00 |
| Mar 31, 2025 | 992,000.00 |
| Mar 31, 2025 | 992,000.00 |
| Dec 31, 2024 | 990,000.00 |
| Dec 31, 2024 | 990,000.00 |
| Sep 30, 2024 | 974,000.00 |
| Sep 30, 2024 | 974,000.00 |
| Jun 30, 2024 | 913,000.00 |
| Jun 30, 2024 | 913,000.00 |
| Mar 31, 2024 | 887,000.00 |
| Mar 31, 2024 | 887,000.00 |
| Dec 31, 2023 | 863,000.00 |
| Dec 31, 2023 | 863,000.00 |